Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer

There is increasing interest in the use of cell-free circulating tumor DNA (ctDNA) as a serum marker for therapy assessment in prostate cancer patients. Prostate cancer is characterized by relatively low numbers of mutations, and, in contrast to many other common epithelial cancers, commercially ava...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Dis Markers
Autores principales: Krumbholz, Manuela, Agaimy, Abbas, Stoehr, Robert, Burger, Maximilian, Wach, Sven, Taubert, Helge, Wullich, Bernd, Hartmann, Arndt, Metzler, Markus
Formato: Artigo
Lenguaje:Inglês
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6930771/
https://ncbi.nlm.nih.gov/pubmed/31915468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/5085373
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares